TOP GUIDELINES OF PF-05221304

 one prior program of chemotherapy for State-of-the-art breast cancer and throughout the full trial, past exposure to any FGFR inhibitor, important surgical procedures or radiotherapy in four months prior to very first dose of research treatment method and having strong inhibitors or inducers of CYP3A4 or CYP2D6. Any of the subsequent cardiac req